54.31USD+0.38%Mkt Cap: —P/E: 58.781d ago
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatme…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value12.47B $
Revenue (TTM)2.44B $
Gross Profit2.35B $
Net Income (TTM)860.62M $
Revenue/Share9.333 USD
Last Price54.31 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.1K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS30161Q1040
Valuation
P/E (Trailing)58.78
P/E (Forward)—
PEG—
EV/EBITDA12.22
EV/Revenue5.12
P/S—
P/B7.16
EPS (TTM)0.92
EPS (Forward)—
52W Range
51.7279% of range55.00
52W High55.00 USD
52W Low51.72 USD
Profitability
Gross Margin96.48%
Oper. Margin39.51%
EBITDA Margin41.89%
Profit Margin35.33%
ROE44.39%
ROA23.97%
Growth
Revenue Growth10.60%
Earnings Growth26.20%
Cash Flow & Leverage
Operating CF1.18B $
CapEx (TTM)—
FCF Margin30.37%
FCF Yield—
Net Debt-673.46M $
Net Debt/EBITDA-0.66
Balance Sheet
Debt/Equity9.00
Current Ratio3.46
Quick Ratio3.24
Book Value/Sh7.408 USD
Cash/Share3.388 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.298.98M
Float214.12M
Insiders1.85%
Institutions107.19%
Technical
SMA 5021.98 (+147.1%)
SMA 20021.24 (+155.7%)
Beta0.42
S&P 52W Chg20.80%
Avg Vol (30d)531
Avg Vol (10d)914
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—